Indications & Dosage

Indications:

Clindacare: Treatment of serious anaerobic infections especially those caused by Bacteroides fragilis. As an alternative to penicillin in some severe staphylococcal and streptococcal infections including staphylococcal osteomyelitis. Because of its potential toxicity, clindamycin should only be used when there is no suitable alternative.
Clindacare: Injection: Antibacterial, Serious infections caused by susceptible Gram-positive organisms, staphylococci (both penicillinase and non-penicillinase producing), streptococci (except Streptococcus faecalis) and pneumococci. It is also indicated in serious infections caused by susceptible anaerobic pathogens.
Clindamycin does not penetrate the blood/brain barrier in therapeutically effective quantities.

Dosage and Administration

Adults: Serious infections due to aerobic gram-positive cocci and the more susceptible anaerobes (NOT generally including Bacteroidesfragilis, Peptococcus species and Costridium perfringens): 600-1200mg/day in 2.3 or 4 equal doses either IM or Iv administration.
More severe infections, particularly those due to proven or suspected Bacteroidesfragilis, Peptococcus species, or Clostridium species other than Clostridium perfringens:1200-2700mg/day in 2,3 or 4 equal doses.
For more serious infections, these doses may have to be increased. In life-thretening situations due to either aerobes or anaerobes these doses may be increased. Doses of as much as 4800mg daily have been given intravenously to adults.
Neonates(Less than 1 month): 15 to 20mg/kg/day in 3 to 4 equal doses. The lower dosage may be adequate for small prematures.
Pediatric patients 1 month of age to 16 years: 20 to 40mg/kg/day in 3 or 4 equal doses either IM or IV administration. The higher doses would be used for more severe infections. As an alternative to dosing on a body weight basis, pediatric patients may be dosed on the basis of square meters body surface: 350mg/m2/day for serious infections and 450mg/m2/day for more severe infections. Parenteral therapy may be changed to oral at the discretion of the physician. In cases of (beta)-hemolytic streptococcal infections, treatment should be continued for at least 10 days. Or as prescribed by the physician.

See insert for complete information